Table 2 Relationship between SELENBP1 expression and clinical characteristics

n

309

310

T stage, n (%)

 T1

5 (1.6%)

15 (4.9%)

 T2

49 (15.9%)

56 (18.1%)

 T3

215 (69.8%)

207 (67%)

 T4

39 (12.7%)

31 (10%)

N stage, n (%)

 N0

169 (54.9%)

182 (59.1%)

 N1

78 (25.3%)

72 (23.4%)

 N2

61 (19.8%)

54 (17.5%)

M stage, n (%)

 M0

230 (83.6%)

229 (84.5%)

 M1

45 (16.4%)

42 (15.5%)

Pathologic stage, n (%)

 Stage I

44 (14.7%)

61 (20.3%)

 Stage II

119 (39.8%)

108 (36%)

 Stage III

92 (30.8%)

87 (29%)

 Stage IV

44 (14.7%)

44 (14.7%)

Primary therapy outcome, n (%)

 PD

20 (14.2%)

13 (8.3%)

 SD

4 (2.8%)

1 (0.6%)

 PR

5 (3.5%)

10 (6.4%)

 CR

112 (79.4%)

132 (84.6%)

Gender, n (%)

 Female

143 (46.3%)

146 (47.1%)

 Male

166 (53.7%)

164 (52.9%)

Race, n (%)

 Asian

8 (4%)

4 (2.4%)

 Black or African American

27 (13.4%)

38 (22.8%)

 White

167 (82.7%)

125 (74.9%)

Age, n (%)

       <  = 65

133 (43%)

136 (43.9%)

    > 65

176 (57%)

174 (56.1%)

Weight, n (%)

     <  = 90

125 (72.3%)

106 (70.7%)

     > 90

48 (27.7%)

44 (29.3%)

Height, n (%)

     < 170

78 (47.6%)

68 (48.6%)

     >  = 170

86 (52.4%)

72 (51.4%)

Residual tumor, n (%)

 R0

218 (92.8%)

232 (90.3%)

 R1

2 (0.9%)

4 (1.6%)

 R2

15 (6.4%)

21 (8.2%)

BMI, n (%)

     < 25

51 (31.1%)

47 (33.6%)

     >  = 25

113 (68.9%)

93 (66.4%)

CEA level, n (%)

     <  = 5

118 (63.1%)

134 (63.8%)

     > 5

69 (36.9%)

76 (36.2%)

Perineural invasion, n (%)

 No

95 (73.6%)

77 (74.8%)

 Yes

34 (26.4%)

26 (25.2%)

Lymphatic invasion, n (%)

 No

168 (60.9%)

163 (57.8%)

 Yes

108 (39.1%)

119 (42.2%)

History of colon polyps, n (%)

 No

174 (67.4%)

190 (69.3%)

 Yes

84 (32.6%)

84 (30.7%)

Colon polyps present, n (%)

 No

110 (70.5%)

97 (68.3%)

 Yes

46 (29.5%)

45 (31.7%)

Neoplasm type, n (%)

 Colon adenocarcinoma

233 (75.4%)

221 (71.3%)

 Rectum adenocarcinoma

76 (24.6%)

89 (28.7%)